CA
NZ
UK
AU
IND
US
Tango Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, disclosing financial and operational information for the third quarter of fiscal year 2026.
Virtus Investment Partners, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting third-quarter total revenues of $197.6 million and net income attributable to the company of $22.1 million.
Eltek Ltd. issued an 8-K on November 9, 2026, announcing that it will report its third-quarter 2026 financial results before the market opens on Tuesday, November 17, 2026, followed by a conference call the same morning at 8:30 a.m. Eastern Time.
Ceva, Inc. filed its third-quarter 2026 earnings press release on November 9, 2026, reporting total revenues of $29.1 million and a sequential royalty revenue increase of 18% for the period ended September 30, 2026.
NovoCure Limited filed a current report on November 9, 2026, disclosing that the U.S. Food and Drug Administration issued a Not Approvable Letter for the company's Premarket Approval application for Optune Mya in a brain metastases indication.
Compugen Ltd. filed its third-quarter 2026 financial results on November 9, 2026, reporting a reduced net loss and providing a clinical and pipeline update covering COM701, rilvegostomig, GS-0321, and the newly introduced UnigenX discovery capability.
Select Water Solutions, Inc. filed an 8-K on November 9, 2026, disclosing its financial and operating results for the quarter ended September 30, 2026, including record Water Infrastructure revenue and the completion of two strategic transactions.
Precision BioSciences, Inc. filed a Form 8-K on November 9, 2026, disclosing details of a public offering of common stock and pre-funded warrants entered into on November 5, 2026, along with the company's projected cash runway through the fourth quarter of 2029.
ProKidney Corp. filed a Form 8-K on November 9, 2026, disclosing its cash and cash equivalents and marketable securities position as of September 30, 2026, and announcing an updated investor presentation furnished under Regulation FD.
Via Transportation, Inc. filed its quarterly report on Form 10-Q with the SEC on November 9, 2026, covering the fiscal quarter ended September 30, 2026, and reporting condensed consolidated financial results for the period.
Please wait processing your request...